All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear from you! 📣

(You can also reach out to me on LinkedIn)

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

THE GOOD
Approvals & Labels

Roche’s subcutaneous Ocrevus formulation lands NHS approval
Monoclonal antibody, multiple sclerosis (MS) - Read more

THE GOOD
Business Development

Aries Science & Technology, Enveric Biosciences licensing agreement; up to $61M in biobucks + royalties
Topical, radiation dermatitis, radiation burn - Read more 

THE GOOD
Clinical Trials

With promising data, Revolution Medicines plans Ph3 push with pancreatic cancer therapy
Small molecule, pancreatic cancer - Read more

Roche shares more Ph1b trial obesity data, plans for Ph2
GLP-1/GIP, obesity - Read more [Paywall]

THE GOOD
Company Launches

Lupin divests their US-based Women's Health business to Evofem Biosciences
Consumer health, women’s health, antimicrobial, bacterial vaginosis (BV), trichomoniasis - Read more

THE GOOD
Fundraises

AusperBio $37M Series A, developing oligonucleotides against hepatitis B
Antisense oligonucleotide, hepatitis B - Read more

MediWound $25M Strategic private placement (PIPE)
Proteolytic enzymes, eschar removal, thermal burns - Read more

Digestiva $18.4M Series A
Protein, protease, food biotech, nutrition - Read more

Bedal International $11M fundraise
Medical device, catheter securement - Read more 

Velentium $15M Growth financing
Medical device, consulting, implantable device, wearable device - Read more

Modicus Prime $3.5M Seed raise
Biologics image analysis, computer vision, quality control - Read more

THE GOOD
Investments

GSK moves into new HQ digs in central London
Headquarters, office space - Read more

Lenz Therapeutics $30M investment from Ridgeback Capital
Small molecule, presbyopia, vision loss - Read more

THE GOOD
IPOs

Artiva Biotherapeutics hopes for a more forgiving IPO environment this time around, $135M targeted raise
Allogeneic NK (natural killer) cell therapy, lupus nephritis - Read more 

THE GOOD
Lawsuits

Vertex Pharmaceuticals wants to pay for fertility support services related to Casgevy treatment prep, sues US government
CRISPR/Cas9 gene-edited therapy, sickle cell disease - Read more [Paywall]

THE GOOD
Mergers & Acquisitions

J&J-partnered Legend Biotech allegedly receives takeover bid
Autologous CAR-T cell therapy, multiple myeloma, cancer - Read more

AstraZeneca officially closes acquisition of Amolyt Pharma
Therapeutics peptides, hypoparathyroidism, endocrine diseases - Read more

Lantheus acquires Meilleur Technologies
Radiopharmaceutical diagnostics, PET imaging agent - Read more

Edwards Lifescience to acquire Innovalve Bio Medical for $300M cash
Transcatheter mitral valve replacement, heart disease - Read more

THE GOOD
Opinions

Big pharma might be facing a huge patent cliff, but they have enough monetary firepower to overcome as “conditions for M&A are favorable”
Patent cliff, mergers & acquisitions - Read more

“Congress must reauthorize FDA Program for Pediatric Rare Diseases“; opinion
Rare pediatric disease priority review voucher program - Read more

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Lexeo Therapeutics gene therapy data is promising, but gaps emerge that worry investors
Gene therapy, Friedreich ataxia - Read more

THE BAD
IPOs

Destiny Pharma goes private to avoid liquidation
Small molecule, antimicrobial, nasal infection - Read more

THE BAD
Regulatory

EMA warns doctors and patients of potential aspiration risk under sedation when taking GLP-1s
GLP-1, aspiration pneumonia, pulmonary aspiration, delayed gastric emptying - Read more

THE BAD
Strategic Plans

Eli Lilly faces “tepid” Alzheimer’s market following Kisunla (donanemab) approval
Monoclonal antibody, Alzheimer’s disease - Read more

THE UGLY
Lawsuits

J&J wants “meritless” class action talc suit dismissed
Talc powder, class action suit - Read more [Paywall]

THE UGLY
Regulatory

FDA considers regulating ultra-processed foods - Read more [Paywall]

THE UGLY
Shortages

BD’s BACTEC blood culture vials in short supply, FDA urges rationing
Diagnostics, blood tests, blood infection - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.